Monopar Therapeutics Inc. Share Price
MNPRMonopar Therapeutics Inc. Stock Performance
Open $77.27 | Prev. Close $78.20 | Circuit Range N/A |
Day Range $76.50 - $78.97 | Year Range $20.16 - $103.77 | Volume 5,538 |
Average Traded $77.15 |
Monopar Therapeutics Inc. Share Price Chart
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
04-Dec-25 | $77.27 | $78.56 | +0.00% |
04-Dec-25 | $77.27 | $78.56 | +1.36% |
02-Dec-25 | $83.00 | $77.50 | -6.46% |
01-Dec-25 | $82.99 | $82.86 | -3.26% |
28-Nov-25 | $91.58 | $85.65 | -2.13% |
26-Nov-25 | $88.70 | $87.52 | -1.72% |
25-Nov-25 | $93.95 | $89.05 | -4.05% |